| human | Q5 |
| P6178 | Dimensions author ID | 01104656077.48 |
| P496 | ORCID iD | 0000-0001-8408-8772 |
| P69 | educated at | South African Medical Association | Q7565731 |
| P106 | occupation | researcher | Q1650915 |
| Q34321402 | A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences |
| Q37026509 | A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only |
| Q37014155 | Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial |
| Q38415905 | Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network |
| Q98650971 | Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy |
| Q37026352 | Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots |
| Q91757237 | Distinct rates and patterns of spread of the major HIV-1 subtypes in Central and East Africa |
| Q39043035 | Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study |
| Q52642470 | Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa. |
| Q36379570 | Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors |
| Q36179320 | Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial |
| Q41906976 | HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya |
| Q28271593 | HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing |
| Q38869669 | HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study |
| Q48064215 | HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia |
| Q42253473 | HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes |
| Q47559042 | Hiv Drug Resistance in Adults Receiving Early Versus Delayed Antiretroviral Therapy: Hptn 052. |
| Q35588154 | Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230 |
| Q36238042 | Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings |
| Q35063655 | Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial |
| Q36693481 | Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy |
| Q36852626 | Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine |
| Q39043026 | Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies |
| Q30404569 | Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants |
| Q35632074 | Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa |
| Q34734833 | Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa |
| Q37021431 | Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study |
| Q39461881 | Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa |
| Q104562758 | Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020 |
| Q46812897 | Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa |
| Q43267414 | Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa |
| Q43236462 | Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? |
Search more.